Top 10 AMCP Sessions Health Execs Should Attend
Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations.
Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations.
It’s not easy to keep track of new and developing medications. This pipeline session will help by focusing on new and emerging specialty medications and exploring their likely role in therapy.
Oncology treatment and delivery is changing rapidly, and it’s critical to stay on top of the trends. This session will update you on the latest delivery model changes.
The high number of RA treatments, and costs associated with many of them, make managing these medications properly a top priority. This session will share tools to help measure the value of RA treatments and how to use those tools to inform cost and utilization management strategies.
Gene therapy present great promise, but they also come at a heavy cost. This session will provide you with insight into the budget implications, and how to prepare.
Having trouble keeping track of all the latest treatment developments in oncology? This session will help. It will review advances in cancer care and provide a health plan’s approach to managing these therapies.
What’s going on in the Alzheimer’s space? This session will explore the drug pipeline, and the potential cost implications.
New players are entering the healthcare system and having a big impact. This session will explore these new players and new innovations from established ones, and the evolving role pharmacists play in optimizing patient outcomes.
Orphan drugs, and the growing number of approvals, has great potential for patients. But these medications also raising significant cost challenges. This article will provide an overview of management strategies.
The industry is bussing about value-based agreements (VBAs), but how common are they really and how often will they be used in the future? This session will provide some insight.
Legislation regarding biosimilars, from the FDA and at the state-level, continues to be updated. This session will explore the regulations you should be watching.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
